The setup, per Lilly's investor disclosures and ClinicalTrials.gov: Duration: 80 weeks of treatment (the longest of any TRIUMPH trial) Population: Adults with obesity (BMI 30) or overweight (BMI 27) plus at least one weight-related comorbidity, without type 2 diabetes Doses: 4 mg, 8 mg, and 12 mg retatrutide vs matched placebo, all once-weekly subcutaneous Primary endpoints: Mean percent change in body weight
A weight loss plateau is when your progress stalls, even as you keep up healthy habits and GLP-1 therapy like semaglutide
It's no longer just a pound here or there
The medication is building to therapeutic levels in your blood
GLP-1 patches are advertised as an easy, non-invasive way to support weight loss
[1] This mechanism reduces the risk of hypoglycemia when used alone, though this risk increases when combined with insulin or sulfonylureas